INTRODUCTION
Mesenchymal tumors of the pancreas are rare and they account for only 1-2% of all primary pancreatic tumors (1) . In order of decreasing frequency, the most commonly reported primary benign or intermediate (borderline) mesenchymal tumors of the pancreas are as follows: schwannoma, inflammatory myofibroblastic tumor, solid and cystic hamartoma, and solitary fibrous tumor (2) . Owing to very few case reports describing primary mesenchymal tumors of the pancreas, no definitive protocol for the treatment of these lesions has been established (3) .
Primary pancreatic angiomyolipoma (AML), a part of a family of mesenchymal tumors, is extremely rare; only a few cases have been reported (2) (3) (4) (5) . Here, we describe the findings from multidetector computed tomography (MDCT) scan, endoscopic ultrasound (EUS), positron emission tomography (PET), magnetic resonance imaging, and provide a pathologic correlation.
CASE REPORT
A 59-year-old female patient was referred to our hospital for treatment of a pancreatic mass. The mass was incidentally noted on a MDCT scan for abdominal trauma work-up. Her physical examination was unremarkable, and laboratory findings including carcinoembryonic antigen and cancer antigen 19-9 levels were within normal limits. In addition to the abdominal MDCT scan, we performed EUS, PET, and MRI for further evaluation of the pancreatic tumor. But on the apparent diffusion coefficient map, the periphery of the tumor did not show low SI. We suggested that high SI on DWI was due to the T2 shine-through artifact, not true diffusion restriction. Dynamic MRI also revealed strong peripheral en- lar to those in our case; however, other results such as imaging findings were quite different, which may be due to hemorrhage.
The mass in that case appeared heterogeneous on US and as an irregular, thick-walled, cystic mass on a CT scan (3) .
Renal AML is located in the renal cortex and exhibits diffusely high echogenicity on US (6) . Most renal AMLs demonstrate fat density (less than -20 HU) on a non-enhanced CT scan, although lipid-poor AMLs show high attenuation. On an enhanced CT scan, they show homogeneous enhancement with a prolonged enhancement pattern (6) (7) (8) . The MRI signals vary depending on the amount of intratumoral fat. However, with the exception of lipid-poor AMLs, most renal AMLs are easily detected using a fat suppression or chemical shift technique (7, 8) .
Hepatic AMLs appear as well-circumscribed, hyperechogenic lesions and may show relative hypervascularity on US (8, 9) .
Unlike renal AMLs, 50% of hepatic AMLs lack an appreciable fat content. As a result, hepatic AMLs show two different imaging types on a CT scan. One type is a lipid-poor hepatic AML with a peripheral angiomyomatous component and soft tissue attenuation. The other type is a lipid-rich hepatic AML with an attenuation value less than -20 HU (9) . In the early phase, hepatic AMLs demonstrate marked enhancement with or without visible large central vessels (10) . On MR, hepatic AMLs have the same imaging characteristics as renal AMLs (7-10). In conclusion, CT and MRI imaging findings of a primary pancreatic AML in our patient differ from those of the first reported primary pancreatic AML as well as renal and hepatic AMLs.
To date, this is the first known report describing CT, EUS, PET and MRI imaging findings of a primary pancreatic AML without hemorrhage. This report has limitations owing to the scarcity of documented cases of primary pancreatic AML. Further evaluation is recommended to establish the general imaging features, standard imaging modalities, and prognostic factors.
